<DOC>
	<DOCNO>NCT02316444</DOCNO>
	<brief_summary>The aim study compare effectiveness two vaccination strategy Hepatitis B virus ( HBV ) subject already infect human immunodeficiency virus ( HIV ) . Researchers plan determine optimal vaccination strategy achieve protective immunity HBV infection HIV-infected adult attend Mulago Hospital 's HIV care clinic . Primary objective ass : 1 . The role CD4-cell count HIV viral load HBV vaccine response . 2 . The role highly active antiretroviral therapy ( HAART ) HBV vaccine response . The secondary objective evaluate whether lack HAART associate high rate loss follow-up .</brief_summary>
	<brief_title>Strategies Prevention Hepatitis B Among HIV Infected Patients Uganda</brief_title>
	<detailed_description>This interventional study researcher recruit HIV positive individual hepatitis B ( HBV negative ) order ass effectiveness hepatitis B vaccine 2 subgroup : 1 . Those receive less 3 month treatment , treatment , highly active antiretroviral drug ( HAART naive ) . 2 . Those receive least 3 month treatment highly active antiretroviral drug ( HAART expose ) . All study participant receive vaccination HBV . There 6-12 clinic visit depend 1 ) whether participant respond standard 3-dose vaccination protocol 2 ) whether suffers clinical condition vaccine relate adverse event would call postponement next vaccine dose . The first visit determine participant eligible study . If eligible , participant receive one dose vaccine follow three visit . The fifth visit collect blood determine whether participant respond 3-dose vaccination protocol . The sixth visit discus outcome vaccination participant . Participants respond favorably 3-dose vaccine protocol exit study point . However , participant fail respond initial 3-dose vaccine protocol , may restart regimen receive another 3 dos vaccine follow schedule . Participants reimburse travel cost clinic schedule clinic visit .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Hepatitis B core antibody ( antiHBc ) antiHBs negative 2 . Age ≥18 year 3 . HIV infected person ( HAART naïve HAART expose ) . HAART enrollees consider HAART expose take medication least 3 month . Participants never HAART HAART &lt; 3months consider HAART naïve . HAART expose enrollee adherence least 95 % . 4 . Ambulatory 5 . Intention attend Mulago HIV/AIDS clinic 18 month 6 . Able willing comply study protocol include provide informed consent 1 . History hypersensitivity vaccine intolerance HBV vaccine component 2 . Previouslyconfirmed diagnosis decompensated liver disease HCC 3 . Serological evidence prior receipt HBV vaccine ( antiHBS positive , antiHBc negative ) document ( clinical ) evidence vaccinate . 4 . Known history HBV infection ( HBsAg and/or antiHBc positive ) . 5 . Inability follow study procedure 6 . If participant chooses consent review medical record</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hepatitis B vaccine HIV infection</keyword>
</DOC>